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Introduction: Invasive aspergillosis of the paranasal sinuses is a rare disease and often misdiagnosed; however, its 
incidence has seen substancial growth over the past 2 decades. Definitive diagnosis of these lesions is based on 
histological examination and fungal culture.
Case Report: An 81-year-old woman with a history of pain in the left maxillary region is presented. The diagnosis 
was invasive maxillary aspergillosis in immunocompetent patient, which was successfully treated with voricona-
zole and surgical debridement. Possible clinical manifestations, diagnostic imaging techniques and treatment used 
are discussed. Since the introduction of voriconazole, there have been several reports of patients with invasive 
aspergillosis who responded to treatment with this new antifungal agent.
Conclusions: We report the importance of early diagnosis and selection of an appropriate antifungal agent to achie-
ve a successful treatment.
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The term “Aspergillosis” refers to an illness due to aller-
gy, airway or lung invasion, cutaneous infection, or ex-
trapulmonary dissemination caused by species of Asper-
gillus. The most frequent site of human infection is the 
lung. Sinusitis is a common disorder affecting approxi-
mately 20% of the population at some time during their 
lives. Fungal sinusitis constitutes 6-9% of all the rhino-
sinusitis. Aspergillus is the most common fungus affec-
ting paranasal sinuses (1). Worlwide, A. fumigatus is the 
most common species, followed by A. flavus. The maxi-
llary sinus is the most common sinus to be affected.
Fungal rhinosinusitis is classified into an invasive and a 
non-invasive form, depending on invasion of the muco-
sal layer and destruction of the bone. The non-invasive 
forms are allergic sinusitis and aspergilloma; this infec-
tion leads to destruction of the sinus mucosa and bone 
atrophy. Invasive aspergillus infections can be either 
limited [chronic or indolent] or fulminant [acute], with 
a rapid malignant course advancing relentlessly to the 
destruction of the nasal cavity, the sinuses and the ad-
jacent structures such as the orbit and the brain within a 
few days (2). The differential diagnosis of fulminant as-
pergillosis must include mucormycosis, pseudomona´s 
orofacial lesions or Wegener´s granulomatosis.
Aspergillus species are ubiquitous in nature, exposure 
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and inhalation of their spores is a frequent event; howe-
ver, the spores are sometimes introduced to the antrum 
via an oroantral communication that occurs at the time 
of a dental procedure such as a root canal perforation or 
a dental extraction. When the spores are inoculated into 
anaerobic sinuses they may become pathogenic (3). Tis-
sue invasion is uncommon and occurs most frequently in 
the setting of immunosuppression associated with the-
rapy for hematologic malignancies, hematopoietic cell 
transplantation, or solid organ transplantation. Neutro-
penia and glucocorticoid use are the most common pre-
disposing factors. Recently, the disease has been increa-
singly reported in immunocompetent patients as well.
Histopathology, invasive aspergillosis is characterized 
by progression of the infection across tissue planes. One 
hallmark of infection is vascular invasion with subse-
quent infarction and tissue necrosis. The prognosis of 
invasive fungal sinusitis is potentially fatal, with an ex-
tremely high mortality rate, particularly in immunocom-
promised patients.
Case Report
An 81-year-old woman with a history of pain in the left 
maxillary region for 3-4 months was referred to our De-
partment of Oral and Maxillofacial Surgery. She had a 
previous history of tooth extraction [maxillary left late-
ral incisor] 5 months before. There was no history sug-
gestive of nasal obstruction, fever, diabetes or recurrent 
infections. The physical examination revealed a mild 
swelling affecting the left side of face (Fig. 1). The pa-
tient showed no evidence of immunosuppression after 
biologic investigations. A panoramic radiograph de-
monstrated opacification of the left maxillary sinus.
CT scan revealed a soft tissue density mass in the left 
maxillary sinus with bone erosion of the anterolateral 
wall, suggestive of a malignancy (Fig. 2). With this sus-
picion, we decided to perform a left Caldwell-Luc proce-
dure under local anaesthesia to biopsy the mass and sent 
for histologic analysis. Histopathological examination 
showed abundant septate fungal hyphae with dichoto-
mous branching suggestive of the Aspergillus species, 
with non-caseating granulomatous inflammation, eosi-
nophils and giant cells.
Fig. 1. The patient presents a mild swelling in the left side 
of face.
Fig. 2. CT scan shows an opacification of left maxillary sinus 
with evidence of bone destruction of the anterolateral wall.
With the diagnosis of fungal sinusitis, we decided to 
operate on the patient. A Caldwell-Luc procedure of the 
maxillary sinus was performed under general anaesthe-
sia and both the granulation tissue and necrotic bone 
were removed, and the natural ostium of the maxillary 
sinus was widened. Macroscopically, bone destruction 
of the anterolateral and posterior walls of the maxillary 
sinus were seen. Histological examination showed the 
typical septate hyphae of Aspergillus with tissue inva-
sion (Fig. 3), and the culture confirmed the species A. 
fumigatus (Fig. 3).
The medical treatment with intravenous voriconazole 
was started the day before surgery and continued for ten 
days [2 doses of 6 mg/kg on day 1, after 4 mg/kg twice 
daily], followed by 200 mg orally twice daily. After 4 
months of oral administration of voriconazole, the pa-
tient remained well and CT scan showed no radiological 
evidence of disease, therefore we decided to interrupt 
the treatment. To this date the patient is asymptomatic 
and shows no clinical or radiographic evidence of recu-
rrent disease.
Discussion
Fungal infections of the paranasal sinuses need to be 
recognised in order to avoid significant mortality and 
morbility. Suspicion can arise in cases of purulent rhi-
nosinusitis which do not respond to two or more courses 
of antibiotics, and on the basis of radiological features. 
Most invasive aspergillosis is caused by A. fumigatus 
[80-90%]; A. flavus [5-10%], A. niger [1-5%] and A. te-
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rreus [1%] are less common (4). Aspergillus fumigatus 
is the most common organism in immunocompetent pa-
tients too (5).
Predisposing factors that promote fungal infections in 
the sinuses include polyps and stagnant secretions besi-
des other factors like neutropenia, inappropriate use of 
antibiotics, immunosuppressive drugs, corticosteroids, 
uncontrolled diabetes mellitus, human immunodeficien-
cy virus infection, trauma, burns, and radiation therapy 
(6). Invasive aspergillosis is a major cause of death in 
immunosuppressed patients, particularly following he-
matopoietic cell transplantation.
In the paranasal sinuses, headache, nasal congestion, fe-
ver, and pain in the face and around the eye are common 
presenting features. Aspergillosis should be suspected 
in patients with refractory or recurrent sinusitis. Inva-
sive aspergillosis originating from the nose and parana-
sal sinuses can cause an intra-orbital and intra-cranial 
growth mainly along the skull base and larger vessels. 
If the orbit becomes involved, additional symptoms may 
include blurred vision, gradual loss of vision, chemosis 
and proptosis. The infection can also extend locally into 
the vasculature and the brain, leading to cavernous sinus 
thrombosis and a variety of central nervous system ma-
nifestations (7). Intracranial and intraorbital extension 
decrease the survival rate and increase surgical morbi-
dity.
Both magnetic resonance imaging [MRI] and CT scan 
can help to establish a diagnosis of invasive fungal sin-
usitis. Opacity of the sinus with or without destruction 
may be demonstrated in the invasive form. Although 
bone erosion and extrasinus extension are the classic CT 
findings highly suggestive of invasive fungal sinusitis, 
these are usually found late in the course of the disease; 
the most common early sign is severe unilateral nasal 
cavity mucosal and soft tissue edema (8). Bone involve-
ment and erosion is more delineated on CT, while soft 
tissue extensions, vascular invasion and cavernous sinus 
involvement are more appreciated on MRI (1). Clinico-
radiological findings can be misleading as the lesions are 
locally destructive and mimic a neoplasm.
Biopsy is necessary to establish the diagnosis. Hyphae 
are typical and specific for each fungus; Mucor presents 
large, broad non-septate hyphae with right-angle bran-
ching, and Aspergillus shows septate hyphae that branch 
at 45º angles. The histology should be specific as to 
whether there is mucosal involvement [invasive] or the 
mucosa is intact [non-invasive disease]. Fungal cultures 
on Sabouraud´s dextrose agar are needed to confirm the 
diagnosis.
Because of its rarity in immunocompetent patients, ac-
curate recognition is critical in order to achieve optimal 
results. Delayed diagnosis and treatment of invasive 
maxillary sinus aspergillosis may lead to a poor thera-
peutic outcome.
Management of invasive aspergillosis therapy is still 
controversial and depends on several factors such as the 
nature of the disease, host immunity and degree of tissue 
invasion. Response to treatment depends on early diag-
nosis and initiation of antifungal therapy augmented by 
surgical debridement. Surgical debridement of abnormal 
tissue in the sinus is recommended for pharmacological 
therapy to reach the infected area. Surgery may improve 
the control of fungal disease and patient survival.
The Infectious Diseases Society of America [IDSA] re-
leased updated guidelines for the treatment of invasive 
aspergillosis in 2008. Voriconazole [broad-spectrum 
triazole] has now become the drug of choice for invasive 
aspergillosis (9). This is due to a better tolerance, increa-
sed efficacy [with a greater likelihood of a complete or 
partial response], improved survival [with a lower mor-
tality rate], and significantly less toxicity when compa-
red with amphotericin B (10). Only a few case reports 
have described the clinical course of invasive fungal si-
nusitis treated with voriconazole (10-13).
The recommended dosing regimen of voriconazole is 6 
Fig. 3. A.Histological examination (hematoxylin and eosin stain) shows abundant septate fungal hyphae with dichotomous 
branching suggestive of the Aspergillus spp., with non-caseating granulomatous inflammation, eosinophils and giant cells; 
B. Microscopic morphology of A. fumigatus (100x; lactophenol blue stain): hyphae are septate and the coniodophore is 
enlarged at the tip, forming a swollen vesicle.
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mg/kg IV every 12 hours on day one followed by 4 mg/
kg IV twice daily, and after, 200 mg orally twice daily. 
The most frequent adverse events are visual disturban-
ces, such as blurred vision, altered visual and colour per-
ception, and photophobia. Other adverse events are skin 
reactions [rash, pruritus or photosensitivity], hepatotoxi-
city, visual hallucinations and confusion. All adverse 
effects described were transient and resolved when the 
drug was discontinued (11). In our case, the patient only 
had skin reactions like pruritus and dryness.
For decades, Amphotericin B deoxycholate has been 
the standard therapy for invasive aspergillosis although 
responses are suboptimal [less than 40 percent] in seve-
rely immuosuppressed patients. Amphotericin B is asso-
ciated with multiple side effects [renal hepatic toxicity, 
anemia, fever and electrolyte abnormalities], which may 
decreased with the use of lipid formulations. In addition, 
amphotericin treatment requires intravenous administra-
tion and extended hospitalization. In patients who are in-
tolerant of voriconazole, the IDSA suggests using a lipid 
formulation of amphotericin B at 5 mg/kg IV per day.
For the treatment of invasive aspergillosis of the sinuses, 
it is recommended to continue oral antifungal therapy 
for at least 4-6 months to prevent recurrence of the di-
sease (13). The duration of therapy depends on several 
factors such as the location of the infection, the patient´s 
underlying disease and the need for further immunosu-
ppression, and the response to therapy. For most patients, 
antifungal therapy will continue for months or even 
years in some cases. Regular post-operative follow-up 
is recommended in all the cases with CT scan and na-
sal endoscopy every 3-4 months. Early diagnosis of re-
current disease requires prolonged systemic antifungal 
chemotherapy.
The differential diagnosis of invasive aspergillosis in-
cludes benign and malignant neoplasms, syphilis, tuber-
culosis, sarcoidosis, Wegener´s granulomatosis, lym-
phoma, mucopyocele and allergic fungal sinusitis.
Conclusions
Invasive maxillary sinus aspergillosis should be consid-
ered in the differential diagnosis of maxillary sinusitis 
that does not respond to standard conservative therapy 
with antibiotics even in immunocompetent patients.
Early diagnosis and therapeutic intervention, with selec-
tion of an appropriate antifungal agent and surgical de-
bridement, is the key to successful treatment of invasive 
aspergillosis.
Voriconazole is recommended for the primary treatment 
of invasive aspergillosis in most patients; this is due to 
a better tolerance, increased efficacy, improved survival, 
and significantly less toxicity with fewer drug-related 
adverse events.
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